Penumbra Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Penumbra Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.40B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.19B | Feb 25, 2026 |
| FY2023 | Dec 31, 2023 | $284.68M | Feb 22, 2024 |
| FY2023 | Sep 30, 2023 | $270.95M | Feb 22, 2024 |
| FY2023 | Jun 30, 2023 | $261.50M | Feb 22, 2024 |
| FY2023 | Mar 31, 2023 | $241.40M | Feb 22, 2024 |
| FY2023 | Dec 31, 2022 | $221.22M | Feb 22, 2024 |
| FY2023 | Sep 30, 2022 | $213.68M | Feb 22, 2024 |
| FY2023 | Jun 30, 2022 | $208.34M | Feb 22, 2024 |
| FY2023 | Mar 31, 2022 | $203.90M | Feb 22, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $96.05M | Feb 27, 2018 |
| FY2017 | Sep 30, 2017 | $83.91M | Feb 27, 2018 |
| FY2017 | Jun 30, 2017 | $80.59M | Feb 27, 2018 |
| FY2017 | Mar 31, 2017 | $73.21M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $73.11M | Feb 27, 2018 |
| FY2017 | Sep 30, 2016 | $67.19M | Feb 27, 2018 |
| FY2017 | Jun 30, 2016 | $65.11M | Feb 27, 2018 |
| FY2017 | Mar 31, 2016 | $57.92M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $54.42M | Feb 28, 2017 |
| FY2016 | Sep 30, 2015 | $50.42M | Feb 28, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $942.44M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $755.00M | Feb 25, 2026 |
| FY2023 | Dec 31, 2023 | $186.99M | Feb 22, 2024 |
| FY2023 | Sep 30, 2023 | $177.72M | Feb 22, 2024 |
| FY2023 | Jun 30, 2023 | $166.86M | Feb 22, 2024 |
| FY2023 | Mar 31, 2023 | $151.07M | Feb 22, 2024 |
| FY2023 | Dec 31, 2022 | $138.43M | Feb 22, 2024 |
| FY2023 | Sep 30, 2022 | $135.33M | Feb 22, 2024 |
| FY2023 | Jun 30, 2022 | $134.04M | Feb 22, 2024 |
| FY2023 | Mar 31, 2022 | $127.42M | Feb 22, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $177.69M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $14.01M | Feb 25, 2026 |
| FY2023 | Dec 31, 2023 | $54.22M | Feb 22, 2024 |
| FY2023 | Sep 30, 2023 | $9.21M | Feb 22, 2024 |
| FY2023 | Jun 30, 2023 | $18.96M | Feb 22, 2024 |
| FY2023 | Mar 31, 2023 | $8.56M | Feb 22, 2024 |
| FY2023 | Dec 31, 2022 | $3.88M | Feb 22, 2024 |
| FY2023 | Sep 30, 2022 | ($2.27M) | Feb 22, 2024 |
| FY2023 | Jun 30, 2022 | ($3.69M) | Feb 22, 2024 |
| FY2023 | Mar 31, 2022 | $79.0K | Feb 22, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $189.25M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $9.28M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $73.55M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $6.08M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | ($7.50M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($38.94M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $47.51M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | ($852.0K) | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $1.17M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | ($1.35M) | Feb 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $36.17M | Feb 26, 2019 |
| FY2018 | Dec 31, 2017 | $31.66M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $23.88M | Feb 26, 2019 |
| FY2017 | Dec 31, 2015 | $18.03M | Feb 27, 2018 |
| FY2016 | Dec 31, 2014 | $15.58M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $14.08M | Mar 8, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $663.42M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $573.99M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $506.45M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $449.72M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $378.33M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $287.07M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $272.73M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $226.39M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $184.32M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $148.30M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $238.66M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $168.48M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $97.33M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($55.66M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $9.50M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($33.24M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $26.65M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $28.81M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $12.69M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | ($12.81M) | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.73M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $21.18M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $15.21M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $19.30M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $21.18M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $24.76M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $22.11M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $9.60M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $12.53M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $13.64M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.83B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.53B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.56B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.37B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.24B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $822.98M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $665.90M | Feb 23, 2021 |
| FY2020 | Jan 1, 2019 | $557.86M | Feb 23, 2021 |
| FY2020 | Dec 31, 2018 | $515.01M | Feb 23, 2021 |
| FY2018 | Dec 31, 2017 | $476.67M | Feb 26, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $398.92M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $382.25M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $377.36M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $372.03M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $290.32M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $185.20M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $180.29M | Feb 23, 2021 |
| FY2020 | Jan 1, 2019 | $135.44M | Feb 23, 2021 |
| FY2020 | Dec 31, 2018 | $92.59M | Feb 23, 2021 |
| FY2018 | Dec 31, 2017 | $76.26M | Feb 26, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.43B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.15B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.18B | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $998.86M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $953.93M | Feb 18, 2025 |
| FY2021 | Dec 31, 2020 | $641.50M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $485.89M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $422.24M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $400.41M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $266.55M | Feb 27, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.75M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $165.83M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $166.27M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $166.05M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $166.39M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $8.37M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $7.66M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $7.81M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $8.18M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Feb 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $237.69M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $60.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $134.86M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $43.90M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $45.91M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $40.62M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $57.52M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $9.06M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.00M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($2.66M) | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.90M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $324.40M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $167.49M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $69.86M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $59.38M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $69.67M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $72.78M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $67.85M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $50.64M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $13.24M | Feb 26, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 25, 2026 |
| FY2023 | Dec 31, 2023 | 1 | Feb 22, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Feb 22, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Feb 22, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Feb 22, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Feb 22, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Feb 22, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Feb 22, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Feb 22, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 25, 2026 |
| FY2023 | Dec 31, 2023 | 1 | Feb 22, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Feb 22, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Feb 22, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Feb 22, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Feb 22, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Feb 22, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Feb 22, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Feb 22, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 39.23M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 38.49M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 38.68M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 38.11M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 37.58M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 36.41M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | 35.00M | Feb 23, 2021 |
| FY2019 | Jun 30, 2019 | 34.44M | Feb 26, 2020 |
| FY2018 | Dec 31, 2018 | 34.44M | Feb 26, 2019 |
| FY2018 | Dec 31, 2017 | 33.69M | Feb 26, 2019 |